{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T10:09:31Z","timestamp":1790071771817,"version":"4.0.1"},"reference-count":79,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2020,10,1]],"date-time":"2020-10-01T00:00:00Z","timestamp":1601510400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,10,1]],"date-time":"2020-10-01T00:00:00Z","timestamp":1601510400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Oncology"],"published-print":{"date-parts":[[2020,10]]},"DOI":"10.1053\/j.seminoncol.2020.07.005","type":"journal-article","created":{"date-parts":[[2020,8,29]],"date-time":"2020-08-29T16:18:44Z","timestamp":1598717924000},"page":"270-277","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":29,"title":["Management of ER positive metastatic breast cancer"],"prefix":"10.1053","volume":"47","author":[{"given":"Nicholas P.","family":"McAndrew","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard S.","family":"Finn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1053\/j.seminoncol.2020.07.005_bib0001","first-page":"394","article-title":"Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"68","author":"Bray","year":"2018","journal-title":"CA Cancer J Clin"},{"key":"10.1053\/j.seminoncol.2020.07.005_bib0002","series-title":"SEER cancer statistics review, 1975-2017","year":"2020"},{"key":"10.1053\/j.seminoncol.2020.07.005_bib0003","first-page":"153","article-title":"On the treatment of inoperable cases of carcinoma of the mamma: suggestions for a new method of treatment, with illustrative cases","volume":"15","author":"Beatson","year":"1896","journal-title":"Trans Med Chir Soc Edinb"},{"key":"10.1053\/j.seminoncol.2020.07.005_bib0004","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1146\/annurev-med-070909-182917","article-title":"Mechanisms of endocrine resistance in breast cancer","volume":"62","author":"Osborne","year":"2011","journal-title":"Annu Rev Med"},{"key":"10.1053\/j.seminoncol.2020.07.005_bib0005","article-title":"Hormonal treatment combined with targeted therapies in endocrine-responsive and HER2-positive metastatic breast cancer","volume":"11","author":"Montagna","year":"2019","journal-title":"Therap Adv Med Oncol"},{"issue":"6","key":"10.1053\/j.seminoncol.2020.07.005_bib0006","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1056\/NEJMoa1109653","article-title":"Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer","volume":"366","author":"Baselga","year":"2012","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1053\/j.seminoncol.2020.07.005_bib0007","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/S1470-2045(14)71159-3","article-title":"The cyclin-dependent kinase 4\/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1\/TRIO-18): a randomised phase 2 study","volume":"16","author":"Finn","year":"2015","journal-title":"Lancet Oncol"},{"issue":"18","key":"10.1053\/j.seminoncol.2020.07.005_bib0008","doi-asserted-by":"crossref","first-page":"1738","DOI":"10.1056\/NEJMoa1609709","article-title":"Ribociclib as first-line therapy for HR-positive, advanced breast cancer","volume":"375","author":"Hortobagyi","year":"2016","journal-title":"N Engl J Med"},{"issue":"32","key":"10.1053\/j.seminoncol.2020.07.005_bib0009","doi-asserted-by":"crossref","first-page":"3638","DOI":"10.1200\/JCO.2017.75.6155","article-title":"MONARCH 3: abemaciclib as initial therapy for advanced breast cancer","volume":"35","author":"Goetz","year":"2017","journal-title":"J Clin Oncol"},{"issue":"20","key":"10.1053\/j.seminoncol.2020.07.005_bib0010","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1056\/NEJMoa1813904","article-title":"Alpelisib for PIK3CA-mutated, hormone receptor-positive advanced breast cancer","volume":"380","author":"Andre","year":"2019","journal-title":"N Engl J Med"},{"issue":"25","key":"10.1053\/j.seminoncol.2020.07.005_bib0011","doi-asserted-by":"crossref","first-page":"3069","DOI":"10.1200\/JCO.2016.67.1487","article-title":"Endocrine therapy for hormone receptor-positive metastatic breast cancer: American Society of Clinical Oncology Guideline","volume":"34","author":"Rugo","year":"2016","journal-title":"J Clin Oncol"},{"issue":"8","key":"10.1053\/j.seminoncol.2020.07.005_bib0012","doi-asserted-by":"crossref","first-page":"1634","DOI":"10.1093\/annonc\/mdy192","article-title":"4th ESO-ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 4)","volume":"29","author":"Cardoso","year":"2018","journal-title":"Ann Oncol"},{"issue":"4","key":"10.1053\/j.seminoncol.2020.07.005_bib0013","doi-asserted-by":"crossref","first-page":"452","DOI":"10.6004\/jnccn.2020.0016","article-title":"Breast Cancer, Version 3.2020, NCCN Clinical Practice Guidelines in Oncology","volume":"18","author":"Gradishar","year":"2020","journal-title":"J Natl Compr Cancer Netw JNCCN"},{"issue":"1","key":"10.1053\/j.seminoncol.2020.07.005_bib0014","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1634\/theoncologist.6-1-4","article-title":"Drug approval summaries: arsenic trioxide, tamoxifen citrate, anastrazole, paclitaxel, bexarotene","volume":"6","author":"Cohen","year":"2001","journal-title":"Oncologist"},{"key":"10.1053\/j.seminoncol.2020.07.005_bib0015","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.pharmthera.2017.12.012","article-title":"Selective estrogen receptor modulators (SERMs) and selective estrogen receptor degraders (SERDs) in cancer treatment","volume":"186","author":"Patel","year":"2018","journal-title":"Pharmacol Ther"},{"issue":"2","key":"10.1053\/j.seminoncol.2020.07.005_bib0016","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1038\/bjc.1971.33","article-title":"A new anti-oestrogenic agent in late breast cancer. An early clinical appraisal of ICI46474","volume":"25","author":"Cole","year":"1971","journal-title":"Br J Cancer"},{"issue":"2","key":"10.1053\/j.seminoncol.2020.07.005_bib0017","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1200\/JCO.1986.4.2.178","article-title":"Randomized trial of bilateral oophorectomy versus tamoxifen in premenopausal women with metastatic breast cancer","volume":"4","author":"Ingle","year":"1986","journal-title":"J Clin Oncol"},{"issue":"9","key":"10.1053\/j.seminoncol.2020.07.005_bib0018","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.1200\/JCO.1986.4.9.1326","article-title":"A randomized comparison of tamoxifen with surgical oophorectomy in premenopausal patients with advanced breast cancer","volume":"4","author":"Buchanan","year":"1986","journal-title":"J Clin Oncol"},{"issue":"24","key":"10.1053\/j.seminoncol.2020.07.005_bib0019","doi-asserted-by":"crossref","first-page":"2431","DOI":"10.1056\/NEJMra023246","article-title":"Aromatase inhibitors in breast cancer","volume":"348","author":"Smith","year":"2003","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1053\/j.seminoncol.2020.07.005_bib0020","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1002\/(SICI)1097-0142(19970215)79:4<730::AID-CNCR10>3.0.CO;2-0","article-title":"A phase III trial comparing anastrozole (1 and 10 milligrams), a potent and selective aromatase inhibitor, with megestrol acetate in postmenopausal women with advanced breast carcinoma. Arimidex Study Group","volume":"79","author":"Buzdar","year":"1997","journal-title":"Cancer."},{"issue":"3","key":"10.1053\/j.seminoncol.2020.07.005_bib0021","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1016\/0959-8049(95)00014-3","article-title":"A randomised trial comparing two doses of the new selective aromatase inhibitor anastrozole (Arimidex) with megestrol acetate in postmenopausal patients with advanced breast cancer","volume":"32A","author":"Jonat","year":"1996","journal-title":"Eur J Cancer"},{"issue":"2","key":"10.1053\/j.seminoncol.2020.07.005_bib0022","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1200\/JCO.1998.16.2.453","article-title":"Letrozole, a new oral aromatase inhibitor for advanced breast cancer: double-blind randomized trial showing a dose effect and improved efficacy and tolerability compared with megestrol acetate","volume":"16","author":"Dombernowsky","year":"1998","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.1053\/j.seminoncol.2020.07.005_bib0023","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1023\/A:1008226721932","article-title":"Letrozole, a new oral aromatase inhibitor: randomised trial comparing 2.5 mg daily, 0.5 mg daily and aminoglutethimide in postmenopausal women with advanced breast cancer. Letrozole International Trial Group (AR\/BC3)","volume":"9","author":"Gershanovich","year":"1998","journal-title":"Ann Oncol"},{"issue":"7","key":"10.1053\/j.seminoncol.2020.07.005_bib0024","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1200\/JCO.2000.18.7.1399","article-title":"Exemestane is superior to megestrol acetate after tamoxifen failure in postmenopausal women with advanced breast cancer: results of a phase III randomized double-blind trial. The Exemestane Study Group","volume":"18","author":"Kaufmann","year":"2000","journal-title":"J Clin Oncol"},{"issue":"10","key":"10.1053\/j.seminoncol.2020.07.005_bib0025","doi-asserted-by":"crossref","first-page":"2596","DOI":"10.1200\/JCO.2001.19.10.2596","article-title":"Superior efficacy of letrozole versus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer: results of a phase III study of the International Letrozole Breast Cancer Group","volume":"19","author":"Mouridsen","year":"2001","journal-title":"J Clin Oncol"},{"issue":"22","key":"10.1053\/j.seminoncol.2020.07.005_bib0026","doi-asserted-by":"crossref","first-page":"3758","DOI":"10.1200\/JCO.2000.18.22.3758","article-title":"Anastrozole is superior to tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: results of a North American multicenter randomized trial. Arimidex Study Group","volume":"18","author":"Nabholtz","year":"2000","journal-title":"J Clin Oncol"},{"issue":"22","key":"10.1053\/j.seminoncol.2020.07.005_bib0027","doi-asserted-by":"crossref","first-page":"3748","DOI":"10.1200\/JCO.2000.18.22.3748","article-title":"Anastrozole versus tamoxifen as first-line therapy for advanced breast cancer in 668 postmenopausal women: results of the Tamoxifen or Arimidex Randomized Group Efficacy and Tolerability study","volume":"18","author":"Bonneterre","year":"2000","journal-title":"J Clin Oncol"},{"issue":"30","key":"10.1053\/j.seminoncol.2020.07.005_bib0028","doi-asserted-by":"crossref","first-page":"4883","DOI":"10.1200\/JCO.2007.14.4659","article-title":"Phase III study comparing exemestane with tamoxifen as first-line hormonal treatment of metastatic breast cancer in postmenopausal women: the European Organisation for Research and Treatment of Cancer Breast Cancer Cooperative Group","volume":"26","author":"Paridaens","year":"2008","journal-title":"J Clin Oncol"},{"issue":"17","key":"10.1053\/j.seminoncol.2020.07.005_bib0029","doi-asserted-by":"crossref","first-page":"8134","DOI":"10.1021\/acs.jmedchem.6b00753","article-title":"Fulvestrant-3 boronic acid (ZB716): an orally bioavailable selective estrogen receptor downregulator (SERD)","volume":"59","author":"Liu","year":"2016","journal-title":"J Med Chem"},{"issue":"6","key":"10.1053\/j.seminoncol.2020.07.005_bib0030","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1634\/theoncologist.7-6-477","article-title":"FDA drug approval summaries: fulvestrant","volume":"7","author":"Bross","year":"2002","journal-title":"Oncologist"},{"issue":"1","key":"10.1053\/j.seminoncol.2020.07.005_bib0031","article-title":"Final overall survival: fulvestrant 500 mg vs 250 mg in the randomized CONFIRM trial","volume":"106","author":"Di Leo","year":"2014","journal-title":"J Natl Cancer Inst"},{"issue":"10063","key":"10.1053\/j.seminoncol.2020.07.005_bib0032","doi-asserted-by":"crossref","first-page":"2997","DOI":"10.1016\/S0140-6736(16)32389-3","article-title":"Fulvestrant 500 mg versus anastrozole 1 mg for hormone receptor-positive advanced breast cancer (FALCON): an international, randomised, double-blind, phase 3 trial","volume":"388","author":"Robertson","year":"2016","journal-title":"Lancet"},{"issue":"27","key":"10.1053\/j.seminoncol.2020.07.005_bib0033","doi-asserted-by":"crossref","first-page":"4530","DOI":"10.1200\/JCO.2008.21.1136","article-title":"Activity of fulvestrant 500 mg versus anastrozole 1 mg as first-line treatment for advanced breast cancer: results from the FIRST study","volume":"27","author":"Robertson","year":"2009","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1053\/j.seminoncol.2020.07.005_bib0034","article-title":"Fulvestrant for hormone-sensitive metastatic breast cancer","volume":"1","author":"Lee","year":"2017","journal-title":"Cochrane Database Syst Rev"},{"issue":"7","key":"10.1053\/j.seminoncol.2020.07.005_bib0035","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1001\/jama.2009.1204","article-title":"Lower-dose vs high-dose oral estradiol therapy of hormone receptor-positive, aromatase inhibitor-resistant advanced breast cancer: a phase 2 randomized study","volume":"302","author":"Ellis","year":"2009","journal-title":"JAMA"},{"issue":"16","key":"10.1053\/j.seminoncol.2020.07.005_bib0036","doi-asserted-by":"crossref","first-page":"1919","DOI":"10.1200\/JCO.2011.38.1095","article-title":"FACT: an open-label randomized phase III study of fulvestrant and anastrozole in combination compared with anastrozole alone as first-line therapy for patients with receptor-positive postmenopausal breast cancer","volume":"30","author":"Bergh","year":"2012","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1053\/j.seminoncol.2020.07.005_bib0037","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1056\/NEJMoa1201622","article-title":"Combination anastrozole and fulvestrant in metastatic breast cancer","volume":"367","author":"Mehta","year":"2012","journal-title":"N Engl J Med"},{"issue":"13","key":"10.1053\/j.seminoncol.2020.07.005_bib0038","doi-asserted-by":"crossref","first-page":"1226","DOI":"10.1056\/NEJMoa1811714","article-title":"Overall survival with fulvestrant plus anastrozole in metastatic breast cancer","volume":"380","author":"Mehta","year":"2019","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1053\/j.seminoncol.2020.07.005_bib0039","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1038\/s41556-018-0205-1","article-title":"mTOR as a central hub of nutrient signalling and cell growth","volume":"21","author":"Kim","year":"2019","journal-title":"Nat Cell Biol"},{"issue":"5","key":"10.1053\/j.seminoncol.2020.07.005_bib0040","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1016\/S1470-2045(17)30109-2","article-title":"Prevention of everolimus-related stomatitis in women with hormone receptor-positive, HER2-negative metastatic breast cancer using dexamethasone mouthwash (SWISH): a single-arm, phase 2 trial","volume":"18","author":"Rugo","year":"2017","journal-title":"Lancet Oncol"},{"issue":"5","key":"10.1053\/j.seminoncol.2020.07.005_bib0041","doi-asserted-by":"crossref","first-page":"R77","DOI":"10.1186\/bcr2419","article-title":"PD 0332991, a selective cyclin D kinase 4\/6 inhibitor, preferentially inhibits proliferation of luminal estrogen receptor-positive human breast cancer cell lines in vitro","volume":"11","author":"Finn","year":"2009","journal-title":"Breast Cancer Res BCR"},{"issue":"21","key":"10.1053\/j.seminoncol.2020.07.005_bib0042","doi-asserted-by":"crossref","first-page":"2052","DOI":"10.1056\/NEJMra1704560","article-title":"Phosphatidylinositol 3-kinase, growth disorders, and cancer","volume":"379","author":"Goncalves","year":"2018","journal-title":"N Engl J Med"},{"issue":"7418","key":"10.1053\/j.seminoncol.2020.07.005_bib0043","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1038\/nature11412","article-title":"Comprehensive molecular portraits of human breast tumours","volume":"490","year":"2012","journal-title":"Nature"},{"issue":"15_suppl","key":"10.1053\/j.seminoncol.2020.07.005_bib0044","volume":"36","author":"Rugo","year":"2018","journal-title":"J Clin Oncol"},{"issue":"11","key":"10.1053\/j.seminoncol.2020.07.005_bib0045","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1158\/2159-8290.CD-18-0264","article-title":"The genetic landscape and clonal evolution of breast cancer resistance to palbociclib plus fulvestrant in the PALOMA-3 trial","volume":"8","author":"O'Leary","year":"2018","journal-title":"Cancer Discov"},{"issue":"2","key":"10.1053\/j.seminoncol.2020.07.005_bib0046","article-title":"Single agent versus combination chemotherapy for metastatic breast cancer","author":"Carrick","year":"2009","journal-title":"Cochrane Database Syst Rev"},{"issue":"10","key":"10.1053\/j.seminoncol.2020.07.005_bib0047","doi-asserted-by":"crossref","first-page":"2567","DOI":"10.1200\/JCO.1995.13.10.2567","article-title":"Randomized comparison of vinorelbine and melphalan in anthracycline-refractory advanced breast cancer","volume":"13","author":"Jones","year":"1995","journal-title":"J Clin Oncol"},{"issue":"23","key":"10.1053\/j.seminoncol.2020.07.005_bib0048","doi-asserted-by":"crossref","first-page":"3407","DOI":"10.1200\/JCO.2006.09.3849","article-title":"Efficacy and safety of ixabepilone (BMS-247550) in a phase II study of patients with advanced breast cancer resistant to an anthracycline, a taxane, and capecitabine","volume":"25","author":"Perez","year":"2007","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1053\/j.seminoncol.2020.07.005_bib0049","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1007\/s10549-004-2468-4","article-title":"Gemcitabine monotherapy as salvage chemotherapy in heavily pretreated metastatic breast cancer","volume":"90","author":"Rha","year":"2005","journal-title":"Breast Cancer Res Treat"},{"issue":"3","key":"10.1053\/j.seminoncol.2020.07.005_bib0050","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1093\/annonc\/mdh097","article-title":"Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCl (CAELYX\/Doxil) versus conventional doxorubicin for first-line treatment of metastatic breast cancer","volume":"15","author":"O'Brien","year":"2004","journal-title":"Ann Oncol"},{"issue":"Suppl 5","key":"10.1053\/j.seminoncol.2020.07.005_bib0051","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1080\/1120009X.2004.11782396","article-title":"Innovative therapy for patients with brain metastases: oral treatments","volume":"16","author":"Kopf","year":"2004","journal-title":"J Chemother"},{"issue":"2","key":"10.1053\/j.seminoncol.2020.07.005_bib0052","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1200\/JCO.1999.17.2.485","article-title":"Multicenter phase II study of capecitabine in paclitaxel-refractory metastatic breast cancer","volume":"17","author":"Blum","year":"1999","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1053\/j.seminoncol.2020.07.005_bib0053","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.clbc.2015.09.007","article-title":"Use of cytotoxic chemotherapy in metastatic breast cancer: putting taxanes in perspective","volume":"16","author":"Sachdev","year":"2016","journal-title":"Clin Breast Cancer"},{"issue":"9769","key":"10.1053\/j.seminoncol.2020.07.005_bib0054","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1016\/S0140-6736(11)60070-6","article-title":"Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study","volume":"377","author":"Cortes","year":"2011","journal-title":"Lancet"},{"issue":"6","key":"10.1053\/j.seminoncol.2020.07.005_bib0055","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1200\/JCO.2013.52.4892","article-title":"Phase III open-label randomized study of eribulin mesylate versus capecitabine in patients with locally advanced or metastatic breast cancer previously treated with an anthracycline and a taxane","volume":"33","author":"Kaufman","year":"2015","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1053\/j.seminoncol.2020.07.005_bib0056","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1007\/s11912-019-0769-3","article-title":"CDK 4\/6 inhibitors in breast cancer: current controversies and future directions","volume":"21","author":"Spring","year":"2019","journal-title":"Curr Oncol Rep"},{"issue":"666","key":"10.1053\/j.seminoncol.2020.07.005_bib0057","article-title":"Mechanisms of resistance to CDK4\/6 inhibitors: potential implications and biomarkers for clinical practice","volume":"9","author":"McCartney","year":"2019","journal-title":"Front Oncol"},{"issue":"13 Suppl","key":"10.1053\/j.seminoncol.2020.07.005_bib0058","article-title":"Abstract CT107: ribociclib in combination with everolimus and exemestane in men and postmenopausal women with HR+\/HER2\u2212 advanced breast cancer after progression on a CDK4\/6 inhibitor: efficacy and safety results from phase II of the TRINITI-1 study","volume":"78","author":"Moulder","year":"2018","journal-title":"Cancer Res"},{"issue":"2","key":"10.1053\/j.seminoncol.2020.07.005_bib0059","doi-asserted-by":"crossref","first-page":"141","DOI":"10.6004\/jnccn.2018.7094","article-title":"Retrospective analysis of treatment patterns and effectiveness of palbociclib and subsequent regimens in metastatic breast cancer","volume":"17","author":"Xi","year":"2019","journal-title":"J Natl Compr Cancer Netw JNCCN"},{"key":"10.1053\/j.seminoncol.2020.07.005_bib0060","first-page":"1","article-title":"Visualization of sequential treatments in metastatic breast cancer","volume":"3","author":"Rocque","year":"2019","journal-title":"JCO Clin Cancer Inform"},{"issue":"7","key":"10.1053\/j.seminoncol.2020.07.005_bib0061","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1111\/cas.12966","article-title":"Bystander killing effect of DS-8201a, a novel anti-human epidermal growth factor receptor 2 antibody-drug conjugate, in tumors with human epidermal growth factor receptor 2 heterogeneity","volume":"107","author":"Ogitani","year":"2016","journal-title":"Cancer Sci"},{"issue":"7","key":"10.1053\/j.seminoncol.2020.07.005_bib0062","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1056\/NEJMoa1914510","article-title":"Trastuzumab deruxtecan in previously treated HER2-positive breast cancer","volume":"382","author":"Modi","year":"2020","journal-title":"N Engl J Med"},{"issue":"17","key":"10.1053\/j.seminoncol.2020.07.005_bib0063","doi-asserted-by":"crossref","first-page":"1887","DOI":"10.1200\/JCO.19.02318","article-title":"Antitumor activity and safety of Trastuzumab Deruxtecan in patients with HER2-Low\u2013Expressing advanced breast cancer: results from a phase Ib study","volume":"38","author":"Modi","year":"2020","journal-title":"J Clin Oncol"},{"issue":"12","key":"10.1053\/j.seminoncol.2020.07.005_bib0064","doi-asserted-by":"crossref","first-page":"2804","DOI":"10.1158\/1078-0432.CCR-17-3452","article-title":"Safety and antitumor activity of pembrolizumab in patients with estrogen receptor\u2013positive\/human epidermal growth factor receptor 2\u2013negative advanced breast cancer","volume":"24","author":"Rugo","year":"2018","journal-title":"Clin Cancer Res"},{"issue":"15_suppl","key":"10.1053\/j.seminoncol.2020.07.005_bib0065","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2018.36.15_suppl.TPS602","article-title":"KEYNOTE-522: phase III study of pembrolizumab (pembro)\u202f+\u202fchemotherapy (chemo) vs placebo\u202f+\u202fchemo as neoadjuvant therapy followed by pembro vs placebo as adjuvant therapy for triple-negative breast cancer (TNBC)","volume":"36","author":"Schmid","year":"2018","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1053\/j.seminoncol.2020.07.005_bib0066","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1007\/s10549-017-4537-5","article-title":"Avelumab, an anti-PD-L1 antibody, in patients with locally advanced or metastatic breast cancer: a phase 1b JAVELIN solid tumor study","volume":"167","author":"Dirix","year":"2018","journal-title":"Breast Cancer Res Treat"},{"issue":"5","key":"10.1053\/j.seminoncol.2020.07.005_bib0067","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1016\/j.trecan.2019.03.005","article-title":"Cell cycle and beyond: exploiting new RB1 controlled mechanisms for cancer therapy","volume":"5","author":"Knudsen","year":"2019","journal-title":"Trends Cancer"},{"issue":"20","key":"10.1053\/j.seminoncol.2020.07.005_bib0068","doi-asserted-by":"crossref","first-page":"1925","DOI":"10.1056\/NEJMoa1607303","article-title":"Palbociclib and letrozole in advanced breast cancer","volume":"375","author":"Finn","year":"2016","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1053\/j.seminoncol.2020.07.005_bib0069","doi-asserted-by":"crossref","first-page":"e173","DOI":"10.1016\/j.clbc.2019.08.009","volume":"20","author":"Rugo","year":"2020","journal-title":"Clin Breast Cancer"},{"issue":"11","key":"10.1053\/j.seminoncol.2020.07.005_bib0070","doi-asserted-by":"crossref","first-page":"1842","DOI":"10.1093\/annonc\/mdz215","article-title":"Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancer","volume":"30","author":"Hortobagyi","year":"2019","journal-title":"Ann Oncol"},{"key":"10.1053\/j.seminoncol.2020.07.005_bib0071","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1038\/s41523-018-0097-z","article-title":"MONARCH 3 final PFS: a randomized study of abemaciclib as initial therapy for advanced breast cancer","volume":"5","author":"Johnston","year":"2019","journal-title":"NPJ Breast Cancer"},{"issue":"7","key":"10.1053\/j.seminoncol.2020.07.005_bib0072","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1016\/S1470-2045(18)30292-4","article-title":"Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): a randomised phase 3 trial","volume":"19","author":"Tripathy","year":"2018","journal-title":"Lancet Oncol"},{"issue":"16","key":"10.1053\/j.seminoncol.2020.07.005_bib0073","doi-asserted-by":"crossref","first-page":"1592","DOI":"10.1056\/NEJMc1911188","article-title":"Ribociclib and endocrine therapy in breast cancer. Reply","volume":"381","author":"Im","year":"2019","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1053\/j.seminoncol.2020.07.005_bib0074","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1056\/NEJMoa1505270","article-title":"Palbociclib in hormone-receptor-positive advanced breast cancer","volume":"373","author":"Turner","year":"2015","journal-title":"N Engl J Med"},{"issue":"20","key":"10.1053\/j.seminoncol.2020.07.005_bib0075","doi-asserted-by":"crossref","first-page":"1926","DOI":"10.1056\/NEJMoa1810527","article-title":"Overall survival with palbociclib and fulvestrant in advanced breast cancer","volume":"379","author":"Turner","year":"2018","journal-title":"N Engl J Med"},{"issue":"24","key":"10.1053\/j.seminoncol.2020.07.005_bib0076","doi-asserted-by":"crossref","first-page":"2465","DOI":"10.1200\/JCO.2018.78.9909","article-title":"Phase III randomized study of ribociclib and fulvestrant in hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: MONALEESA-3","volume":"36","author":"Slamon","year":"2018","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.1053\/j.seminoncol.2020.07.005_bib0077","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1056\/NEJMoa1911149","article-title":"Overall survival with ribociclib plus fulvestrant in advanced breast cancer","volume":"382","author":"Slamon","year":"2020","journal-title":"N Engl J Med"},{"issue":"25","key":"10.1053\/j.seminoncol.2020.07.005_bib0078","doi-asserted-by":"crossref","first-page":"2875","DOI":"10.1200\/JCO.2017.73.7585","article-title":"MONARCH 2: abemaciclib in combination with fulvestrant in women with HR+\/HER2- advanced breast cancer who had progressed while receiving endocrine therapy","volume":"35","author":"Sledge","year":"2017","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1053\/j.seminoncol.2020.07.005_bib0079","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1001\/jamaoncol.2019.4782","article-title":"The effect of abemaciclib plus fulvestrant on overall survival in hormone receptor-positive, ERBB2-negative breast cancer that progressed on endocrine therapy-MONARCH 2: a randomized clinical trial","volume":"6","author":"Sledge","year":"2019","journal-title":"JAMA Oncol"}],"container-title":["Seminars in Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0093775420300828?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0093775420300828?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T12:55:05Z","timestamp":1758804905000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0093775420300828"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10]]},"references-count":79,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2020,10]]}},"alternative-id":["S0093775420300828"],"URL":"https:\/\/doi.org\/10.1053\/j.seminoncol.2020.07.005","relation":{},"ISSN":["0093-7754"],"issn-type":[{"value":"0093-7754","type":"print"}],"subject":[],"published":{"date-parts":[[2020,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Management of ER positive metastatic breast cancer","name":"articletitle","label":"Article Title"},{"value":"Seminars in Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1053\/j.seminoncol.2020.07.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}